US 12,440,475 B2
Hodgkin lymphoma therapy
Thomas Mehrling, Riehen (CH); Rosaria De Filippi, Naples (IT); and Antonio Pinto, Naples (IT)
Assigned to Purdue Pharmaceutical Products L.P., Stamford, CT (US)
Filed by Purdue Pharmaceutical Products L.P., Stamford, CT (US)
Filed on Aug. 9, 2023, as Appl. No. 18/446,522.
Application 17/679,308 is a division of application No. 16/341,089, granted, now 11,266,631, issued on Mar. 8, 2022, previously published as PCT/EP2016/074331, filed on Oct. 11, 2016.
Application 18/446,522 is a continuation of application No. 17/679,308, filed on Feb. 24, 2022, granted, now 11,766,424.
Prior Publication US 2024/0082220 A1, Mar. 14, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4184 (2006.01); A61K 45/06 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01)
CPC A61K 31/4184 (2013.01) [A61K 47/68031 (2023.08); A61P 35/00 (2018.01); A61K 45/06 (2013.01)] 18 Claims
 
1. A method of treating Hodgkin lymphoma in a patient identified in need thereof, comprising orally administering to said patient a therapeutically effective amount of a compound of formula I or a pharmacologically acceptable salt thereof:

OG Complex Work Unit Chemistry